Literature DB >> 6405010

Structural and cell-associated proteins of Lassa virus.

J C Clegg, G Lloyd.   

Abstract

Lassa virus was purified from culture fluids of infected CV-1 monkey kidney cells and its structural proteins analysed by polyacrylamide gel electrophoresis. Stained gels showed a typical arenavirus profile, with a prominent protein of molecular weight 60000, corresponding to the nucleocapsid protein N, and two faint broad bands with molecular weights of 45000 and 38000, the envelope glycoproteins G1 and G2. G1 and G2 were shown to be glycosylated by their ability to bind concanavalin A to nitrocellulose transfers of the separated proteins ('Western blots'). N and G2 bound antibody from guinea-pig or human convalescent sera but G1 was inactive, presumably as a result of denaturation. This technique also revealed other apparently virus-specific minor bands with molecular weights of 76000 and 68000. When Western blots of proteins of infected cells which had been lysed in SDS were probed with anti-Lassa virus serum or stained for glycoproteins, four virus-specific bands were apparent: the N, G1 and G2 proteins seen in purified virus, and a glycoprotein of molecular weight 72000 which probably corresponds to the envelope protein precursor (GPC) seen in other arenavirus systems. Immunoprecipitates from infected CV-1 cells labelled with [35S]methionine contained three major virus-specific proteins: the nucleocapsid protein N and proteins of 36000 and 24000 molecular weight (designated fN1 and fN2). Similar immunoprecipitates from Vero cells contained fN1 and fN2 and only very low levels of N. The polypeptides fN1 and fN2 are most probably fragments of N, since Western blots probed with anti-Lassa virus serum showed that lysis of cells in non-ionic detergent rather than SDS results in the appearance of fN2 with concomitant reduction or disappearance of N. These fragments do not exist in the intact cell, but are found as a consequence of rather specific proteolysis upon disruption under non-denaturing conditions. The proteolytic activity responsible was refractory to inhibition by phenylmethylsulphonyl fluoride, aprotinin, pepstatin A or sodium bisulphite, and was more active in Vero than in CV-1 cells.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6405010     DOI: 10.1099/0022-1317-64-5-1127

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  15 in total

1.  Epitope mapping of the Lassa virus nucleoprotein using monoclonal anti-nucleocapsid antibodies.

Authors:  F T Hufert; W Lüdke; H Schmitz
Journal:  Arch Virol       Date:  1989       Impact factor: 2.574

2.  Some biochemical properties of Lassa virus RNA and polypeptides.

Authors:  I S Lukashevich; N N Lemeshko; T A Stelmakh; V P Golubev; E P Stcheslyenok
Journal:  Med Microbiol Immunol       Date:  1986       Impact factor: 3.402

3.  Evolutionary biology of a Lassa virus complex.

Authors:  J P Gonzalez; A J Georges; M P Kiley; D M Meunier; C J Peters; J B McCormick
Journal:  Med Microbiol Immunol       Date:  1986       Impact factor: 3.402

4.  Use of monoclonal antibody for the detection of Lassa virus antibody and antigen in patients with Lassa fever.

Authors:  H Schmitz; H R Wolf
Journal:  Med Microbiol Immunol       Date:  1986       Impact factor: 3.402

5.  The C-terminal region of lymphocytic choriomeningitis virus nucleoprotein contains distinct and segregable functional domains involved in NP-Z interaction and counteraction of the type I interferon response.

Authors:  Emilio Ortiz-Riaño; Benson Yee Hin Cheng; Juan Carlos de la Torre; Luis Martínez-Sobrido
Journal:  J Virol       Date:  2011-10-05       Impact factor: 5.103

Review 6.  VaxCelerate II: rapid development of a self-assembling vaccine for Lassa fever.

Authors:  Pierre Leblanc; Leonard Moise; Cybelle Luza; Kanawat Chantaralawan; Lynchy Lezeau; Jianping Yuan; Mary Field; Daniel Richer; Christine Boyle; William D Martin; Jordan B Fishman; Eric A Berg; David Baker; Brandon Zeigler; Dale E Mais; William Taylor; Russell Coleman; H Shaw Warren; Jeffrey A Gelfand; Anne S De Groot; Timothy Brauns; Mark C Poznansky
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

7.  Shedding of soluble glycoprotein 1 detected during acute Lassa virus infection in human subjects.

Authors:  Luis M Branco; Jessica N Grove; Lina M Moses; Augustine Goba; Mohammed Fullah; Mambu Momoh; Randal J Schoepp; Daniel G Bausch; Robert F Garry
Journal:  Virol J       Date:  2010-11-09       Impact factor: 4.099

8.  Cleavage of the Junin virus nucleoprotein serves a decoy function to inhibit the induction of apoptosis during infection.

Authors:  Svenja Wolff; Stephan Becker; Allison Groseth
Journal:  J Virol       Date:  2012-10-17       Impact factor: 5.103

9.  Detection of Lassa virus antinucleoprotein immunoglobulin G (IgG) and IgM antibodies by a simple recombinant immunoblot assay for field use.

Authors:  J Ter Meulen; K Koulemou; T Wittekindt; K Windisch; S Strigl; S Conde; H Schmitz
Journal:  J Clin Microbiol       Date:  1998-11       Impact factor: 5.948

10.  Machupo virus polypeptides: identification by immunoprecipitation.

Authors:  I S Lukashevich; N N Lemeshko
Journal:  Arch Virol       Date:  1985       Impact factor: 2.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.